Individuals aged 6 to less than 18 years old with a diagnosis of chronic plaque psoriasis for at least 6 months, may qualify to participate.

The study consists of 4 parts, each with distinct populations:

• Part 1: for adolescents (aged 12 to less than 18 years old) with severe disease involving 20% or more body surface area (or 10% or more body surface area that includes facial or genital areas).
• Part 2: for adolescents (aged 12 to less than 18 years old) with moderate to severe disease involving 10% or more body surface area.
• Part 3: for children (aged 6 to less than 12 years old) with severe disease involving 20% or more body surface area (or 10% or more body surface area that includes facial or genital areas).
• Part 4: for children (aged 6 to less than 12 years old) with moderate to severe disease involving 10% or more body surface area.

As the study progresses, some parts may no longer be enrolling.

Parts 1, 3, and 4 are open-label and all participants will receive investigational medication (active study drug), via injection. In Part 2, participants will receive one of two active study drugs during Period A; medication assignment may then change for Period B. Study medication and study-related procedures will be provided at no cost. Reimbursement for study-related expenses will also be provided.

Study participation in Parts 1, 3, and 4 will be about 65 weeks and involve about 9 visits to the study centre, plus a follow-up phone call.

In Part 2, study duration may be longer (81 weeks) and involve additional visits to the study centre.

Call the study centre near you, or register now.